TTRNA-xALT

N/A

Report date: 2024/02/23 15:47:25

Base Information

Drug NameTTRNA-xALT
Drug Alias NameTumor-specific ex vivo expanded autologous lymphocyte transferxALT
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsNeuroblastomaOligodendrogliomaMedulloblastoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Florida
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Florida
Inactive CompaniesN/A
Active IndicationsNeuroblastomaOligodendrogliomaMedulloblastoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A